Загрузка...
B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes
Costimulatory interactions control T cell activation at sites of activated antigen-presenting cells, including B cells. Blockade of the CD28/CD80/CD86 costimulatory axis with CTLA4Ig (abatacept) is widely used to treat certain autoimmune diseases. While transiently effective in subjects with new-ons...
Сохранить в:
| Опубликовано в: : | JCI Insight |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Clinical Investigation
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478438/ https://ncbi.nlm.nih.gov/pubmed/30830871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.126136 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|